Sophie V. Vandebroek's most recent trade in Idexx Laboratories, Inc. was a trade of 945 Common Stock done at an average price of $333.9 . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 333.90 per share. | 17 Feb 2026 | 945 | 2,112 (0%) | 0% | 333.9 | 315,536 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 945 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 628.65 per share. | 17 Feb 2026 | 945 | 1,167 (0%) | 0% | 628.6 | 594,070 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 628.56 per share. | 17 Feb 2026 | 519 | 648 (0%) | 0% | 628.6 | 326,223 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 283.59 per share. | 09 May 2025 | 1,279 | 2,446 (0%) | 0% | 283.6 | 362,712 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2025 | 1,279 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 491.34 per share. | 09 May 2025 | 1,279 | 1,167 (0%) | 0% | 491.3 | 628,425 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 600 | 600 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 262 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 262 | 1,167 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 257 | 257 | - | - | Restricted Stock Unit | |
| Revvity | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 1,338 | 5,088 (0%) | 0% | 0 | Common Stock | |
| Revvity | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 1,074 | 3,750 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 420.44 per share. | 27 Nov 2024 | 344 | 905 (0%) | 0% | 420.4 | 144,630 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Nov 2024 | 224 | 1,249 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 609 | 609 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 262 | 262 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 257 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 257 | 1,473 (0%) | 0% | 0 | Common Stock | |
| Revvity | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,218 | 2,676 (0%) | 0% | 0 | Common Stock | |
| Revvity | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 977 | 1,458 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 245.79 per share. | 05 Mar 2024 | 1,404 | 2,620 (0%) | 0% | 245.8 | 345,089 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 1,404 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 562.98 per share. | 05 Mar 2024 | 1,404 | 1,216 (0%) | 0% | 563.0 | 790,427 | Common Stock |
| Revvity | Vandebroek V. Sophie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 264 | 481 (0%) | 0% | 0 | Common Stock | |
| Revvity | Vandebroek Sophie V. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 217 | 217 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 645 | 645 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 257 | 257 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 344 | 1,216 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 344 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 469.02 per share. | 04 May 2023 | 2,187 | 872 (0%) | 0% | 469.0 | 1,025,740 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 2,187 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.62 per share. | 04 May 2023 | 2,187 | 3,059 (0%) | 0% | 206.6 | 451,878 | Common Stock |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 04 May 2023 | 500 | 8,173 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 945 | 945 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 344 | 568 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2022 | 224 | 344 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2022 | 224 | 872 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 723 | 723 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 224 | 224 | - | - | Restricted Stock Unit |